---
title: "VK2735 in Chronic weight management: VK2735-101 oral part C"
description: "Formulary evidence on VK2735 in Chronic weight management: VK2735-101 oral part C. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 43 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence/vk2735-101-oral-part-c"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: VK2735-101 oral part C

<a id="heading-3.1.10"></a>

## 3.1.10 VK2735-101 Oral Part C

<a id="heading-3.1.10.1"></a>

### 3.1.10.1 Objective

<a id="topic-3.1.10.1-1"></a>

#### Oral formulation: safety and tolerability of a once-daily tablet for 28 days

> “The primary objective of the study is to evaluate the safety and tolerability of VK2735 administered as an oral tablet once daily for 28 days. The secondary objective is to evaluate the pharmacokinetics of orally administered VK2735 in healthy subjects. Exploratory pharmacodynamic measures include assessments of changes in body weight and plasma glucose.”

Source: [Viking Therapeutics oral phase 1 initiation release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Study-to-Evaluate-Oral-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.10.1-2"></a>

#### Oral formulation: objectives stated in the poster

> “The primary objective of the study was to evaluate the safety and tolerability of multiple doses of VK2735 administered as an oral tablet once daily for 28 days, and to identify suitable doses for further clinical development. The secondary objective was to evaluate the pharmacokinetics of oral VK2735 in healthy subjects.”
> “We developed an oral tablet formulation that demonstrated encouraging plasma exposures in model studies. We report herein results from a first in human evaluation of this formulation in healthy volunteers with BMI ≥30.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.1-3"></a>

#### Oral formulation: Part C in the ClinicalTrials.gov record

> “Part C (Multiple Ascending Dose [MAD], PO) will be conducted to assess the safety, tolerability, PK and PD profiles in otherwise healthy, but obese, participants who have a BMI ≥30 kg/m2 following daily oral administration of VK2735 or matched placebo administered for 28 consecutive days”

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="heading-3.1.10.2"></a>

### 3.1.10.2 Location and Study Date

<a id="topic-3.1.10.2-1"></a>

#### Initiation in March 2023

> “SAN DIEGO, March 28, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it has initiated a Phase 1 clinical study to evaluate a novel oral formulation of the company's dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist VK2735.”

Source: [Viking Therapeutics oral phase 1 initiation release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Study-to-Evaluate-Oral-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.10.2-2"></a>

#### Results through 40 mg in March 2024 and through 100 mg at ObesityWeek 2024

> “SAN DIEGO, March 26, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive results from the company's Phase 1 multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735”

Source: [Viking Therapeutics oral phase 1 results release (2024)](https://ir.vikingtherapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

> “Highlights from one poster presentation include new data from the company's Phase 1 multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735 dosed daily for 28 days, including results for the study's 60 mg, 80 mg, and 100 mg daily treatment cohorts.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.2-3"></a>

#### Investigator sites named on the poster

> “1Orange County Research Center, CA; 2CMAX, Australia; 3Novotech, Australia; 4Viking Therapeutics, Inc., CA”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.2-4"></a>

#### Study dates and site in the ClinicalTrials.gov record (Parts A, B, and C)

| Field | Registry value |
| --- | --- |
| Primary completion (actual) | “2024-11-04” |
| Study completion (actual) | “2024-12-03” |
| Site city | “Adelaide” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="heading-3.1.10.3"></a>

### 3.1.10.3 Study Design

<a id="topic-3.1.10.3-1"></a>

#### Oral formulation: extension of the subcutaneous phase 1 study

> “The Phase 1 MAD study of oral VK2735 is an extension of the company's Phase 1 single ascending dose (SAD)/MAD trial of VK2735 administered subcutaneously. The oral portion of the trial is a randomized, double-blind, placebo-controlled study in healthy adults with a minimum body mass index of 30 kilograms per meter squared.”

Source: [Viking Therapeutics oral phase 1 results release (2024)](https://ir.vikingtherapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.10.3-2"></a>

#### Oral formulation: dose escalation after review of each cohort

> “Safety Review Committee (SRC) meetings will be held prior to dose escalation for Part A (SAD), Part B (MAD), and Part C (MAD-PO) cohorts in the study. The decisions on dose escalation will be based on safety and laboratory data from each cohort.”

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

> “DLRT: Dose Level Review Team Meeting”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.3-3"></a>

#### Oral formulation: dose escalation continued beyond 40 mg after the interim results

> “Based on the encouraging weight loss, as well as the safety and tolerability results to date, the company has elected to continue further dose escalation in this study.”

Source: [Viking Therapeutics oral phase 1 results release (2024)](https://ir.vikingtherapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.10.3-4"></a>

#### Oral formulation: exploratory daily to every-other-day cohort

> “An exploratory cohort of subjects was also evaluated to assess changes to dose regimen. Subjects in this cohort were titrated to 80 mg daily doses and subsequently transitioned to a lower exposure regimen (80 mg QoD) from Day 15 – 28.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="heading-3.1.10.4"></a>

### 3.1.10.4 Eligibility Criteria

<a id="topic-3.1.10.4-1"></a>

#### Oral formulation: healthy adults with a body mass index of at least 30 kg/m2

> “The Phase 1 trial is a randomized, double-blind, placebo-controlled study in healthy adults with a minimum body mass index (BMI) of 30 kg/m2.”

Source: [Viking Therapeutics oral phase 1 initiation release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Study-to-Evaluate-Oral-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.10.4-2"></a>

#### Inclusion and exclusion criteria in the ClinicalTrials.gov record (Parts A, B, and C)

> “Participants must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the Investigator”
> “Participant body weight must have been stable (no change greater than 5%) for a minimum 8 weeks prior to Screening”
> “History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, diabetes, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant”

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="topic-3.1.10.4-3"></a>

#### Age range in the ClinicalTrials.gov record (Parts A, B, and C)

| Field | Registry value |
| --- | --- |
| Minimum age | “18 Years” |
| Maximum age | “65 Years” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="heading-3.1.10.5"></a>

### 3.1.10.5 Treatment

<a id="topic-3.1.10.5-1"></a>

#### Oral formulation: titration schedules by cohort

> “Subjects treated with VK2735 were titrated to final doses as indicated: 2.5 mg cohort = 2.5 daily x 4 weeks; 5 mg cohort = 2.5 mg daily x 1 wk, 5 mg daily x 3 wks; 10 mg cohort = 5 mg daily x 1 wk, 10 mg daily x 3 wks; 20 mg cohort = 15 mg daily x 1 wk, 20 mg daily x 3 wks; 40 mg cohort = 20 mg daily x 1 wk, 40 mg daily x 3 wks; 60 mg cohort = 40 mg daily x 1 wk, 60 mg daily x 3 wks; 80 mg cohort = 60 mg daily x 1 wk, 80 mg daily x 3 wks; 100 mg cohort = 80 mg daily x 1 wk, 100 mg daily x 3 wks.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.5-2"></a>

#### Oral formulation: daily and every-other-day regimens at 80 mg

> “80 mg Cohort A = 60 mg daily x 1 wk, 80 mg daily x 3 wks; 80 mg Cohort B = 60 mg daily x 1 wk, 80 mg daily x 1 wk, 80 mg QoD x 2 wks.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.5-3"></a>

#### Oral formulation: arms in the ClinicalTrials.gov record

| Arm label | Registry description |
| --- | --- |
| “VK2735 (Part C)” | “Escalating doses of VK2735 administered daily (PO) in healthy participants.” |
| “VK2735 (Part C )” | “Placebo administered orally daily for 28 days in healthy participants” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="heading-3.1.10.6"></a>

### 3.1.10.6 Study Outcomes

<a id="heading-3.1.10.6.1"></a>

#### 3.1.10.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.10.6.1-1"></a>

##### Oral formulation: safety and tolerability as the primary objective

> “The primary objective of the study was to evaluate the safety and tolerability of VK2735 administered as an oral tablet once daily for 28 days. Exploratory pharmacodynamic measures included assessments of changes in body weight and other metrics.”

Source: [Viking Therapeutics oral phase 1 results release (2024)](https://ir.vikingtherapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.10.6.1-2"></a>

##### Registered primary outcome measure (Parts A, B, and C)

| Outcome | Measure | Time frame |
| --- | --- | --- |
| Primary | “Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs)” | “8 days” |
| Secondary | “Evaluate the Pharmacokinetic profile of VK2735” | “29 days” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="topic-3.1.10.6.1-3"></a>

##### Oral formulation: exploratory proportion with at least 5% weight loss

> “An exploratory assessment of the proportion of subjects achieving at least 5% weight loss after 28 days demonstrated that up to 100% of VK2735-treated subjects achieved ≥5% weight loss, compared with 0% for placebo.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="heading-3.1.10.7"></a>

### 3.1.10.7 Statistical Analysis Description

<a id="heading-3.1.10.7.1"></a>

#### 3.1.10.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.10.7.1-1"></a>

##### Oral formulation: participants randomized and analyzed

> “A total of 92 subjects were randomized and received at least one dose of study drug or placebo. Of these, 89 had at least one scheduled post-baseline body weight assessment.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.7.1-2"></a>

##### Oral formulation: participants analyzed by cohort

| Group | Efficacy population | Safety population |
| --- | --- | --- |
| Placebo | “(n=18)” | “(n=19)” |
| VK2735 2.5 mg | “(n=8)” | “(n=8)” |
| VK2735 5 mg | “(n=6)” | “(n=7)” |
| VK2735 10 mg | “(n=6)” | “(n=6)” |
| VK2735 20 mg | “(n=8)” | “(n=8)” |
| VK2735 40 mg | “(n=7)” | “(n=8)” |
| VK2735 60 mg | “(n=9)” | “(n=9)” |
| VK2735 80 mg | “(n=9)” | “(n=9)” |
| VK2735 100 mg | “(n=9)” | “(n=9)” |

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.7.1-3"></a>

##### Actual enrollment in the ClinicalTrials.gov record (Parts A, B, and C)

| Field | Registry value |
| --- | --- |
| Enrollment (actual) | “92” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="heading-3.1.10.7.2"></a>

#### 3.1.10.7.2 Description of Analysis Sets

<a id="topic-3.1.10.7.2-1"></a>

##### Oral formulation: efficacy and safety populations

> “Population includes all randomized subjects who received at least one dose of study drug and had at least one planned post-baseline body weight assessment.”
> “Safety population, includes all randomized subjects who received at least one dose of study drug or placebo.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.7.2-2"></a>

##### Oral formulation: mixed model for repeated measures

> “Statistical analysis: Change and percent change from baseline were analyzed using a mixed model for repeated measures (MMRM) with treatment and visit as factors along with treatment-visit interaction, and baseline weight as a covariate.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.7.2-3"></a>

##### Oral formulation: tests for weight change and responder proportions

> “Least squares mean.”
> “Two-sided t test using mixed model for repeated measures.”
> “Fisher's exact test.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="heading-3.1.10.8"></a>

### 3.1.10.8 Results

<a id="heading-3.1.10.8.1"></a>

#### 3.1.10.8.1 Participant Disposition

<a id="topic-3.1.10.8.1-1"></a>

##### Oral formulation: early study discontinuation by cohort

| Group | Discontinued study early |
| --- | --- |
| Placebo (n=19) | “2 (11%)” |
| VK2735 2.5 mg (n=8) | “0 (0%)” |
| VK2735 5 mg (n=7) | “1 (14%)” |
| VK2735 10 mg (n=6) | “0 (0%)” |
| VK2735 20 mg (n=8) | “0 (0%)” |
| VK2735 40 mg (n=8) | “1 (13%)” |
| VK2735 60 mg (n=9) | “1 (11%)” |
| VK2735 80 mg A (n=9) | “1 (11%)” |
| VK2735 80 mg B (n=9) | “0 (0%)” |
| VK2735 100 mg (n=9) | “0 (0%)” |

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="heading-3.1.10.8.2"></a>

#### 3.1.10.8.2 Baseline Characteristics

<a id="topic-3.1.10.8.2-1"></a>

##### Oral formulation: mean baseline characteristics by cohort

| Group | Age | Sex, M:F (%) | White (%) | Weight (kg) | BMI (kg/m2) |
| --- | --- | --- | --- | --- | --- |
| Placebo (n=19) | “38” | “47:53” | “68” | “99” | “36” |
| VK2735 2.5 mg (n=8) | “34” | “63:37” | “75” | “102” | “36” |
| VK2735 5 mg (n=7) | “29” | “43:57” | “71” | “97” | “34” |
| VK2735 10 mg (n=6) | “35” | “17:83” | “100” | “97” | “36” |
| VK2735 20 mg (n=8) | “35” | “63:37” | “88” | “111” | “36” |
| VK2735 40 mg (n=8) | “33” | “25:75” | “63” | “89” | “33” |
| VK2735 60 mg (n=9) | “44” | “33:67” | “89” | “108” | “37” |
| VK2735 80 mg (n=9) | “44” | “56:44” | “100” | “102” | “35” |
| VK2735 100 mg (n=9) | “44” | “44:56” | “67” | “103” | “35” |

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="heading-3.1.10.8.3"></a>

#### 3.1.10.8.3 Efficacy Results

<a id="topic-3.1.10.8.3-1"></a>

##### Oral formulation: weight loss at day 28 through 100 mg

> “Cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline, ranging up to 8.2%. Cohorts receiving VK2735 also demonstrated reductions in mean body weight relative to placebo, ranging up to 6.8%. Persistent weight loss effects were observed at follow-up visits through Day 57, ranging up to 8.3% from baseline, four weeks after the last dose of VK2735 was administered.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.8.3-2"></a>

##### Oral formulation: change in body weight by cohort at day 28

| Measure | Placebo (n=18) | 2.5 mg (n=8) | 5 mg (n=6) | 10 mg (n=6) | 20 mg (n=8) | 40 mg (n=7) | 60 mg (n=9) | 80 mg (n=9) | 100 mg (n=9) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mean baseline body weight | “98.3 kg” | “102.3 kg” | “95.3 kg” | “97.1 kg” | “111.3 kg” | “90.0 kg” | “107.7 kg” | “102.0 kg” | “102.7 kg” |
| Mean change from baseline body weight | “-1.4 kg” | “-0.3 kg” | “-0.8 kg” | “-1.3 kg” | “-3.6 kg” | “-4.8 kg” | “-4.4 kg” | “-5.3 kg” | “-8.2 kg” |
| Mean percent change from baseline | “-1.4 %” | “-0.3 %” | “-0.8 %” | “-1.1 %” | “-3.5 %” | “-5.1 %” | “-4.1 %” | “-5.2 %” | “-8.2 %” |
| Placebo-adjusted mean percent change from baseline | “-” | “1.0 %” | “0.6 %” | “0.3 %” | “-2.2 %” | “-3.7 %” | “-2.7 %” | “-3.9 %” | “-6.8 %” |
| p-value vs. placebo | “-” | “-” | “-” | “-” | “0.0174” | “0.0001” | “0.0026” | “<0.0001” | “<0.0001” |
| Percent reporting at least 5% weight loss | “0 %” | “0 %” | “0 %” | “0 %” | “25 %” | “57 %” | “38 %” | “63 %” | “100 %” |
| p-value vs. placebo for at least 5% weight loss | “-” | “-” | “-” | “-” | “0.0933” | “0.0033” | “0.0243” | “0.0011” | “<0.0001” |

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.8.3-3"></a>

##### Oral formulation: interim results through 40 mg

> “Cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline, ranging up to 5.3%. Cohorts receiving VK2735 also demonstrated reductions in mean body weight relative to placebo, ranging up to 3.3%. For doses ≥10 mg, placebo-adjusted reductions in mean body weight were maintained or improved at Day 34, six days after the last dose of VK2735 was administered, ranging up to 3.6% relative to placebo.”

Source: [Viking Therapeutics oral phase 1 results release (2024)](https://ir.vikingtherapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.10.8.3-4"></a>

##### Oral formulation: daily to every-other-day transition at 80 mg

> “Despite reduction in VK2735 exposure, significant reductions in body weight were observed, with subjects reporting mean body weight change of -4.0% from baseline at Day 28 (p<0.0001). Weight loss trajectory from Day 15 to Day 28 in this cohort was similar to that observed in the cohort of subjects receiving 80 mg daily doses and may suggest the potential for lower dose maintenance regimens.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.8.3-5"></a>

##### Oral formulation: progressive weight loss and durability through day 57

> “Progressive weight loss observed through Day 28 at doses ≥20 mg, no plateau. Trends suggests further weight reduction possible with longer dosing period. Following last dose at D28, majority of weight loss maintained through D57.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.8.3-6"></a>

##### Oral formulation: pharmacokinetic exposure across doses

> “Plasma exposures increase predictably through 100 mg dose level”
> “Oral exposures demonstrate linearity with increasing dose.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.8.3-7"></a>

##### Oral formulation: satiety and decreased appetite

> “Majority of subjects dosed ≥40 mg reported reduced appetite/increased satiety, including all subjects in 100 mg cohort.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.8.3-8"></a>

##### Oral formulation: summary in the corporate presentation

> “Exploratory transition from 80 mg QD to 80 mg QoD suggests feasibility of lower dose maintenance regimens”
> “Majority of weight loss maintained 4 weeks after final dose”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="heading-3.1.10.8.4"></a>

#### 3.1.10.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.10.8.5"></a>

#### 3.1.10.8.5 Safety Results

<a id="topic-3.1.10.8.5-1"></a>

##### Oral formulation: adverse events through 100 mg

> “Oral VK2735 demonstrated encouraging safety and tolerability following repeated dosing. The majority of observed adverse events (99%) were reported as mild or moderate. All treatment emergent gastrointestinal (GI) related adverse events (100%) were also reported as mild or moderate. Nausea was reported among subjects receiving both VK2735 (32%) and placebo (11%). Among subjects receiving VK2735, all reported nausea (100%) was characterized as mild (0% moderate to severe). Vomiting was reported in 3/73 (4%) VK2735 treated subjects and 0/19 (0%) subjects receiving placebo.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.8.5-2"></a>

##### Oral formulation: adverse event summary by cohort

| Event | Placebo (n=19) | 2.5 mg (n=8) | 5 mg (n=7) | 10 mg (n=6) | 20 mg (n=8) | 40 mg (n=8) | 60 mg (n=9) | 80 mg A (n=9) | 80 mg B (n=9) | 100 mg (n=9) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Treatment-emergent adverse events | “16 (84%)” | “6 (75%)” | “6 (86%)” | “4 (67%)” | “6 (75%)” | “7 (88%)” | “9 (100%)” | “9 (100%)” | “8 (89%)” | “9 (100%)” |
| Drug-related treatment-emergent adverse events | “11 (58%)” | “4 (50%)” | “4 (57%)” | “3 (50%)” | “4 (50%)” | “7 (88%)” | “6 (67%)” | “9 (100%)” | “7 (78%)” | “9 (100%)” |
| Serious adverse events | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “1 (11%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” |

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.8.5-3"></a>

##### Oral formulation: gastrointestinal adverse events by cohort

| Event | Placebo (n=19) | 2.5 mg (n=8) | 5 mg (n=7) | 10 mg (n=6) | 20 mg (n=8) | 40 mg (n=8) | 60 mg (n=9) | 80 mg A (n=9) | 80 mg B (n=9) | 100 mg (n=9) | Combined (n=73) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Nausea, mild | “2 (11%)” | “0 (0%)” | “1 (14%)” | “0 (0%)” | “2 (25%)” | “2 (25%)” | “2 (22%)” | “6 (67%)” | “4 (44%)” | “6 (67%)” | “23 (32%)” |
| Vomiting | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “1 (11 %)” | “1 (11 %)” | “1 (11 %)” | “3 (4 %)” |
| Diarrhea | “4 (21 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “1 (13 %)” | “0 (0 %)” | “1 (11 %)” | “1 (11 %)” | “1 (11 %)” | “1 (11 %)” | “5 (7 %)” |
| Constipation | “3 (16 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “3 (33 %)” | “2 (22 %)” | “1 (11 %)” | “4 (44 %)” | “10 (14 %)” |

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.8.5-4"></a>

##### Oral formulation: severity of adverse events through 100 mg

> “The majority (99%) of treatment emergent adverse events (TEAEs) reported to date have been mild or moderate, with the majority (90%) reported as mild. Similarly, all observed gastrointestinal (GI) adverse events have been reported as mild or moderate, with the majority (84%) reported as mild.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.8.5-5"></a>

##### Oral formulation: interim safety through 40 mg

> “Among subjects receiving VK2735, all treatment emergent adverse events (TEAEs) reported to date have been mild or moderate, with the majority (76%) reported as mild.”
> “In addition, no serious adverse events (SAEs) have been reported to date.”

Source: [Viking Therapeutics oral phase 1 results release (2024)](https://ir.vikingtherapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="heading-3.1.10.9"></a>

### 3.1.10.9 Study Limitations

<a id="topic-3.1.10.9-1"></a>

#### Summary: study limitations

VK2735-101 Part C was the first administration of the oral tablet formulation, in otherwise healthy adults with a body mass index of at least 30 kg/m2 who took VK2735 once daily for 28 days with follow-up to day 57. Safety and tolerability were the primary objectives, and body weight was an exploratory measure. Each VK2735 cohort had 6 to 9 participants and the pooled placebo group had 17 to 19, depending on the analysis; the every-other-day cohort at 80 mg had 9 participants. The tablet doses studied (2.5 to 100 mg) differ from the doses carried into phase 3 (27.5, 35, and 55 mg), and 28 days of dosing does not show where weight loss plateaus. Part C has no registry record of its own: the ClinicalTrials.gov record for NCT05203237 describes Part C in its detailed description but registers a single primary outcome, safety after single subcutaneous doses over 8 days, and reports an actual enrollment of 92 for Parts A, B, and C, the same number the poster reports as randomized in Part C alone. The interim release of March 2024 stated that “no serious adverse events (SAEs) have been reported to date” for cohorts through 40 mg; the poster reports one serious adverse event in the 60 mg cohort (1 of 9, 11%) without describing it. Results are available only in press releases, a corporate presentation, and a congress poster, with no peer-reviewed publication and no results posted to the registry.

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf); [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024); [Viking Therapeutics oral phase 1 results release (2024)](https://ir.vikingtherapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735); [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237); [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="topic-3.1.10.9-2"></a>

#### Oral formulation: potential for improvement with higher doses or longer dosing noted on the poster

> “Dose response shows increased proportion of subjects with at least 3% and 5% weight loss with increasing VK2735 dose. Potential to improve with higher dose and/or longer dosing period.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
